Human LILRB2/CD85d/ILT4 Domain1&2 Protein

Cat. No. LIL-HM12D



Description	
Source	Recombinant Human LILRB2/CD85d/ILT4 Domain1&2 Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Gln22-Val229.
Accession	Q8N423-1
Molecular Weight	The protein has a predicted MW of 24.2 kDa. Due to glycosylation, the protein migrates to 25-30 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC
Formulation and Storage	


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles.

Assay Data

Tris-Bis PAGE




Human LILRB2 Domain 1&2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Cat. No. LIL-HM12D

KAGTUS


Assay Data



The purity of Human LILRB2 Domain 1&2 is greater than 95% as determined by SEC-HPLC.

ELISA Data


Human LILRB2 Domain1&2, His Tag ELISA 0.05µg Human LILRB2 Domain1&2, His Tag Per Well



Immobilized Human LILRB2 Domain1&2, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Anti-LILRB2 Antibody, hFc Tag with the EC50 of 16.6ng/ml determined by ELISA (QC Test).

Blocking Data

Inhibition of Human LILRB2 Domain1&2 and HLA-G Binding 0.2µg Human LILRB2 Domain1&2, His Tag Per Well



Serial dilutions of Anti-LILRB2 Antibody were added into Human LILRB2 Domain1&2, His Tag: Biotinylated Human HLA-G Complex Tetramer, His Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.43µg/ml.